![Jan Peter Olofsson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jan Peter Olofsson
Gründer bei Redoxis AB
Aktive Positionen von Jan Peter Olofsson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Redoxis AB
![]() Redoxis AB Medical SpecialtiesHealth Technology Redoxis AB focuses on preclinical drug development and validation in autoimmune diseases. The firm focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The company was founded by David Rikard Martinsson Holmdahl and Jan Peter Olofsson in 2007 and is headquartered in Gothenburg, Sweden. | Direktor/Vorstandsmitglied | 01.01.2007 | - |
Gründer | 01.01.2007 | - | |
Vorstandsvorsitzender | 01.01.2007 | - | |
ProNoxis AB
![]() ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Vorstandsvorsitzender | - | - |
Direktor/Vorstandsmitglied | 28.12.2009 | - | |
Corporate Officer/Principal | 28.12.2009 | 26.07.2011 |
Karriereverlauf von Jan Peter Olofsson
Ehemalige bekannte Positionen von Jan Peter Olofsson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Biovitrum AB
![]() Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Direktor/Vorstandsmitglied | - | 31.12.2009 |
Corporate Officer/Principal | - | - | |
Arexis AB
![]() Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Corporate Officer/Principal | - | - |
Ausbildung von Jan Peter Olofsson
University of Lund | Doctorate Degree |
University of Gothenburg | Masters Business Admin |
Statistik
International
Schweden | 7 |
Operativ
Director/Board Member | 3 |
Corporate Officer/Principal | 3 |
Chief Executive Officer | 2 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Biovitrum AB
![]() Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
Arexis AB
![]() Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Health Technology |
ProNoxis AB
![]() ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Health Technology |
Redoxis AB
![]() Redoxis AB Medical SpecialtiesHealth Technology Redoxis AB focuses on preclinical drug development and validation in autoimmune diseases. The firm focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The company was founded by David Rikard Martinsson Holmdahl and Jan Peter Olofsson in 2007 and is headquartered in Gothenburg, Sweden. | Health Technology |
- Börse
- Insiders
- Jan Peter Olofsson
- Erfahrung